The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in...

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The Wnt/β-catenin signaling pathway is crucial for stem cell regulation and is often dysregulated in cancers like osteosarcoma (OS).
• Targeting this pathway with tankyrase inhibitors presents a promising therapeutic strategy for OS treatment.

Purpose of the Study:

• To evaluate the efficacy of the tankyrase inhibitor JW74 in osteosarcoma cell lines.
• To investigate the molecular and functional effects of JW74 on OS cells, including its impact on cell growth, cell cycle, apoptosis, differentiation, and microRNA expression.

Main Methods:

• Treatment of three OS cell lines (KPD, U2OS, SaOS-2) with JW74.
• Analysis of molecular changes including AXIN2 stabilization and nuclear β-catenin levels.
• Assessment of functional outcomes such as cell growth, cell cycle progression, apoptosis (caspase-3), and osteogenic differentiation.
• Quantification of let-7 family microRNA expression.

Main Results:

• JW74 treatment led to AXIN2 stabilization and reduced nuclear β-catenin in OS cells.
• JW74 inhibited cell growth, delayed cell cycle progression, and induced apoptosis across all tested cell lines.
• JW74 promoted osteogenic differentiation in U2OS cells (normally resistant) and enhanced differentiation in other OS cell lines.
• JW74 significantly upregulated let-7 family microRNAs.

Conclusions:

• Tankyrase inhibition via JW74 effectively reduces osteosarcoma cell growth and induces differentiation.
• The observed effects may be partly mediated by the upregulation of let-7 microRNAs.
• These findings support tankyrase inhibition as a potential novel therapeutic strategy for osteosarcoma.